Enrico is a pioneer in the life sciences with a history of recognizing and developing new technologies that change markets. He is currently a director of AbleTo, Aventura, Medicalis, mPulseMobile, MedOptions and Spinal Kenetics. He also served as a director to SensAble Technologies (sold to 3D Systems) and was a board observer for Interlace Medical (sold to Hologic), Tandem Diabetes (NASDAQ) and Transcend Medical.
Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology.
Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker. In addition he is an advisor to several companies in the field of regenerative medicine and molecular diagnostics and is a board observer for Interlace Medical.
Enrico earned his master’s degree in molecular and cell biology from the University of Connecticut.
Enrico Picozza can be reached at firstname.lastname@example.org.